Introduction: Mantle cell lymphoma (MCL) is a rare, aggressive non-Hodgkin lymphoma (NHL) that accounts for 5‒7% of all lymphomas. In patients with B-cell NHL, COVID-19 mortality was a concern early in the pandemic when access to vaccines and supportive treatments was limited, though COVID-19 mortality rates generally decreased over time. Data on COVID-19 and MCL are limited; multiple clinical trials enrolled patients with MCL during the pandemic, but interpreting results can be challenging without knowledge of COVID-19 impact in these patients. This study aims to describe trends in mortality over time and specific patient attributes associated with death in patients with MCL with or without a COVID-19 diagnosis.

Methods: A retrospective cohort study used Optum CDM data in patients with MCL between 12/1/2019 and 6/30/2024; index date was defined as the later of first MCL diagnosis date or 12/1/2019. COVID-19 vaccination status was based on vaccination claim records; time to vaccination was defined as the time from the date of first vaccine approval by the FDA (12/11/2020) to the date of first COVID-19 vaccination. Annualized all-cause mortality rate (AMR) was defined as total number of deaths per total number of patient-years and was calculated by COVID-19 diagnosis cohorts and by COVID-19 vaccination status. AMR was calculated for the pre-vaccine period (12/1/2019–11/30/2020) and 4 time periods thereafter (12/1/2020–6/30/2024).

Results: A total of 1527 patients were included (≥1 COVID-19 diagnosis, n=349; no COVID-19 diagnosis, n=1178): median age 73 and 72 years (with and without COVID-19 diagnosis, respectively), age ≤65 years (22.6% and 28.4%), age 66‒75 years (44.7% and 42.8%), age ≥76 years (32.7% and 28.8%), male (64.5% and 66.1%), and mean Charlson Comorbidity Index (2.97 and 2.86). For patients with MCL and COVID-19 diagnosis, AMR decreased over time during the study (from a peak of 88.4% in the pre-vaccine period, to 41.7% in the immediate post-vaccine period [12/1/2020–11/30/2021], to 20.7% at end of study period [12/1/2023–6/30/2024]). For patients without a COVID-19 diagnosis, AMR remained steady throughout the study period (16.4% pre-vaccine; 12.5–17.4% [post-vaccine periods]). In patients with COVID-19 diagnosis, AMR increased with older age (33.7% in patients ≥76 years vs 10.4% in patients ≤65 years), no vaccination (40.2% vs 11.8% for vaccinated patients), Medicare Advantage (30.3% vs 5.6% with commercial plan; likely age-related), and no prior stem cell transplantation (SCT; 27.9% vs 13.2% in patients with prior SCT). Sex, race/ethnicity, region and time to first vaccine dose did not seem to impact AMR.

Conclusions: This retrospective database analysis demonstrated a trend of decreased all-cause mortality over time among patients with MCL and a COVID-19 diagnosis, reflecting similar trends in the general population as access to multiple vaccine options and supportive treatments improved. The most prominent factors associated with death in patients with MCL and COVID-19 diagnosis were older age, no vaccination, and no prior SCT. Study limitations include those inherent to claims data, sample size, and inability to detail cause of death.

This content is only available as a PDF.
2025
Sign in via your Institution